Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
RESEARCH TOOLSreports
4D Molecular Therapeutics (FDMT) Stock Price & Analysis
229 Followers
FDMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.44 - $36.25
Previous Close$18.52
Volume760.70K
Average Volume (3M)868.39K
Market Cap
$957.55M
Enterprise Value$445.81M
Total Cash (Recent Filing)$525.91M
Total Debt (Recent Filing)$14.17M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 08, 2024EPS Estimate
-$0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding51,703,412
10 Day Avg. Volume585,768
30 Day Avg. Volume868,387
Standard Deviation0.35
R-Squared0.16
Alpha-0.00336
Financial Highlights & Ratios
Price to Book (P/B)1.97
Price to Sales (P/S)57.23
Price to Cash Flow (P/CF)-10.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.80
Enterprise Value/Gross Profit21.51
Enterprise Value/Ebitda-4.89
Forecast
1Y Price Target
$52.50Price Target Upside186.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
4D Molecular Therapeutics News
PremiumCompany Announcements
4D Molecular Therapeutics to Present PRISM Trial Interim Data
Bulls Say, Bears Say
Bulls Say
Financial PositionFDMT ended Q1 with $589 million in cash, cash equivalents, and marketable securities, reflecting a strong financial position.
Market PotentialThe wetAMD program addresses limitations of approved/investigational drugs and can potentially confer a >$4B commercial opportunity.
Safety And EfficacyThe safety profile of 4D-150 remains highly favorable, with no severe adverse events reported.
Bears Say
Durability ConcernsDelay of 52-week data readout raised durability concerns.
Investor SentimentNew safety signal worsened investor sentiment.
Management CredibilityLack of transparency around a second loading dose impacted management's credibility.
---
Ownership Overview
14.30% Insiders
13.33% Mutual Funds
13.74% Other Institutional Investors
58.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $9.44 and its highest was $36.25 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
Currently, no data Available
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 13 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on May 09, 2024. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.741 by $0.081.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -$0.68.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 51,703,410 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.741. Following the earnings report the stock price went up 0.234%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Among the largest hedge funds holding 4D Molecular Therapeutics’s share is RA Capital Management. It holds 4D Molecular Therapeutics’s shares valued at 161M.
---
4D Molecular Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.50 (186.10% Upside)
$52.50 (186.10% Upside)
Hedge Fund Trend
Decreased
By 771.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.3%
Last 30 Days ▲ 26.2%
Last 30 Days ▲ 26.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
158.13%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.
---
FDMT Stock 12 Month Forecast
Average Price Target
$52.50
▲(186.10% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Editas Medicine
―
Best Analysts Covering FDMT
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
-0.78%
reiterated a buy rating 2 months ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -0.78% per trade.
---